MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review

March 2021 | 51 pages | ID: MAE9D773CBBEN
GlobalData

Abstracts

MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It consists of a dry powder formulation of human insulin delivered from small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. The company has manufacturing facility in Danbury, Connecticut and sells product to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.

MannKind Corp Key Recent Developments

Mar 10,2021: MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference
Feb 25,2021: MannKind reports 2020 fourth quarter and full year financial results
Feb 18,2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
Dec 10,2020: James S. Shannon transitions to chairman of the board of directors for MannKind
Dec 01,2020: MannKind and MidCap amend credit facility

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

MannKind Corp - Key Facts
MannKind Corp - Key Employees
MannKind Corp - Key Employee Biographies
MannKind Corp - Major Products and Services
MannKind Corp - History
MannKind Corp - Company Statement
MannKind Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
MannKind Corp - Business Description
Business Segment: Collaborations and Services
Overview
Performance
Business Segment: Commercial Product Sales
Overview
Performance
R&D Overview
MannKind Corp - Corporate Strategy
MannKind Corp - SWOT Analysis
SWOT Analysis - Overview
MannKind Corp - Strengths
MannKind Corp - Weaknesses
MannKind Corp - Opportunities
MannKind Corp - Threats
MannKind Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MannKind Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 10, 2021: MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference
Feb 25, 2021: MannKind reports 2020 fourth quarter and full year financial results
Feb 18, 2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
Dec 10, 2020: James S. Shannon transitions to chairman of the board of directors for MannKind
Dec 01, 2020: MannKind and MidCap amend credit facility
Nov 30, 2020: Sabrina Kay appointed to MannKind Board of Directors
Nov 04, 2020: MannKind reports 2020 third quarter financial results
Aug 31, 2020: Kevin Kaiserman joins MannKind as Vice President, Medical Affairs and Safety
Aug 05, 2020: MannKind reports 2020 second quarter financial results
Jul 20, 2020: Alejandro Galindo joins MannKind as Chief Commercial Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

MannKind Corp, Key Facts
MannKind Corp, Key Employees
MannKind Corp, Key Employee Biographies
MannKind Corp, Major Products and Services
MannKind Corp, History
MannKind Corp, Other Locations
MannKind Corp, Subsidiaries
MannKind Corp, Key Competitors
MannKind Corp, Ratios based on current share price
MannKind Corp, Annual Ratios
MannKind Corp, Annual Ratios (Cont...1)
MannKind Corp, Annual Ratios (Cont...2)
MannKind Corp, Interim Ratios
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MannKind Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

MannKind Corp, Performance Chart (2016 - 2020)
MannKind Corp, Ratio Charts
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021